drugset / Trial / NCT06645522

Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke

NCT06645522

Phase 4 Not yet recruiting 1200 enrolled Yi Yang
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of edaravone dexborneol in treating acute ischemic stroke.

Timeline

Start
2024-10-30
Primary completion
2026-10-30
Completion
2027-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Edaravone Dexborneol Unknown 36 mg Other

Indications